. 2020 Nov 4;54:108. doi: 10.11606/s1518-8787.2020054001828

Table 3. Univariate analysis of factors associated with current and former smoker in PLHIV attended in Specialized Care Services in Belo Horizonte/MG, 2015 – 2017, compared to nonsmokers) (n = 234).

Characteristics		Current smoker		p^a	Former smoker		p^a
Characteristics		n = 128	%	p^a	n = 106	%	p^a
Sociodemographic and economic
Gender				0.177			0.863
	Male	97	25. 8		88	23.4
	Female	31	36.0		18	20.9
Age (years)				0.116			0.991
	≤ 33	74	31.1		52	21.8
	> 33	54	24.1		54	24.1
Marital status				0.884			0.749
	Single/divorced/widowed	103	28.0		83	22.6
	Married/Stable Relationship	25	26.6		23	24.5
Race/skin color				0.071			0.259
	White	21	18.9		33	29.7
	Non-white	104	30.1		73	21.1
Schooling level (years)
	≤ 9	39	32.5	0.004	39	32.5	< 0.001
	10–12	51	28.7	0.167	37	20.8	0.285
	≥ 13	38	23.3		29	17.8
Employment				< 0.001			0.003
	Yes	61	22.6		54	20.0
	No	67	34.9		52	27.1
Economic class
	C, D, E	80	27.7	0.720	67	23.2	0.653
	A,B	43	26.7		35	21.7
Behaviors and life habits
HIV risk				0.249			0.025
	MSM	59	26.6		44	19.8
	Other^b	48	28.4		48	28.4
Alcohol use prior month				0.015			0.276
	Yes	95	32.3		59	20.1
	No	32	19.4		47	28.5
Alcohol use in life				0.002			0.011
	Yes	112	30.4		91	24.7
	No	16	17.4		15	16.3
Marijuana use in life				< 0.001			< 0.001
	Yes	87	43.5		58	29.0
	No	40	15.4		47	18.1
Cocaine use in life				< 0.001			< 0.001
	Yes	66	47.8		39	28.3
	No	61	19.0		66	20.6
Crack use in life				< 0.001			0.001
	Yes	23	60.5		12	31.6
	No	104	24.8		93	22.1
I use condom prior month				0.056			0.005
	Yes	64	25.4		46	18.3
	No	36	30.5		34	28.8
Religious belief				0.019			0.694
	Yes	91	24.9		86	23.5
	No	35	37.2		20	21.3
Clinics and laboratories
Comorbidity^c				0.117			0.318
	Yes	32	33.0		24	24.7
	No	96	26.3		82	22.5
Co-infection^d				0.138			0.608
	Yes	15	37.5		9	22.5
	No	113	27.0		95	22.7
Signs/symptoms of anxiety or depression				< 0.001			0.236
	Yes	66	37.9		39	22.4
	No	62	21.5		67	23.3
Clinical classification^e				0.883			0.128
	No AIDS (A/B)	101	28.4		74	20.8
	With aids (C)	23	24.7		27	29.0
CD4+LT Count				0.334			0.628
	≤ 200 (cells/ml)	29	24.0		30	24.8
	> 200 (cells/ml)	88	29.7		62	20.9
Viral load (copies/ml)				0.161			0.399
	≤ 100,000	92	30.5		62	20.5
	> 100,000	25	21.7		31	27.0
ART-Related
Therapeutic regimen
	TDF/3TC/EFV	75	25.8		68	23.4
	TDF/3TC/DTG	43	30.1	0.328	33	23.1	0.788
	Other schemes	10	35.7	0.347	5	17.9	0.745
ART start time				0.825			0.805
	≤ 60	63	27.0		55	23.6
	> 60	65	28.4		51	22.3
Adherence				0.134			0.805
	Yes	47	23.9		45	22.8
	No	71	30.3		51	21.8
Self-reported ADR				0.298			0.697
	Yes	104	28.1		84	22.7
	No	15	22.4		15	22.4
Self-reported ADR number				0.118			0.069
	≤ 3	59	25.2		47	20.1
	>3	60	29.6		52	25.6
Follow-up service
	HEM	48	27.6	0.640	43	24.7	0.664
	CTA	45	25.6	0.290	39	22.2	0.832
	CTR	35	31.3		24	21.4

Pearson's Chi-square test. Values with statistical significance are presented in bold.

LT-CD4⁺: T-CD4+ lymphocytes; MSM: men who have sex with men; IDI: injectable drug user; TDF: tenofovir; 3TC: lamivudine; EFV: efavirenz; DTG: dolutegravir; ART: antiretroviral therapy; ADR: adverse drug reaction; HIV: human immunodeficiency virus.

other risks: hemophiliacs, transfusion and occupational.

Comorbidities were considered those recorded at the first visit (diabetes mellitus – DM, systemic arterial hypertension – SAH, dyslipidemia, cancers or other).

The co-infection considered in the first consultation corresponds to: tuberculosis, leishmaniasis, leprosy or other.

Clinical classification according to the criteria of the Centers for Disease Control and Prevention adapted; A: asymptomatic, B: symptomatic, C: aids-defining symptoms.